Your browser doesn't support javascript.
loading
Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
Patel, Rishi K; Bandera, Francesco; Venneri, Lucia; Porcari, Aldostefano; Razvi, Yousuf; Ioannou, Adam; Chacko, Liza; Martinez-Naharro, Ana; Rauf, Muhammad U; Knight, Daniel; Brown, James; Petrie, Aviva; Wechalekar, Ashutosh; Whelan, Carol; Lachmann, Helen; Muthurangu, Vivek; Guazzi, Marco; Hawkins, Philip N; Gillmore, Julian D; Fontana, Marianna.
Afiliação
  • Patel RK; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Bandera F; Cardiac Rehabilitation and Heart Failure Unit, Cardiology University Department, Scientific Institute for Research, Hospitalization and Healthcare MultiMedica, Sesto San Giovanni, Milan, Italy.
  • Venneri L; Department of Biomedical Sciences for Health, University of Milano, Milan, Italy.
  • Porcari A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Razvi Y; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Ioannou A; Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Italy, Trieste, Italy.
  • Chacko L; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Martinez-Naharro A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Rauf MU; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Knight D; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Brown J; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Petrie A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Wechalekar A; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Whelan C; Eastman Dental Institute, University College London, University Street, London, United Kingdom.
  • Lachmann H; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Muthurangu V; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Guazzi M; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Campus, London, United Kingdom.
  • Hawkins PN; Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Gillmore JD; Cardiac Rehabilitation and Heart Failure Unit, Cardiology University Department, Scientific Institute for Research, Hospitalization and Healthcare MultiMedica, Sesto San Giovanni, Milan, Italy.
  • Fontana M; Department of Biomedical Sciences for Health, University of Milano, Milan, Italy.
JAMA Cardiol ; 9(4): 367-376, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38446436
ABSTRACT
Importance Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis.

Objective:

To use CPET to characterize the spectrum of functional phenotypes in patients with ATTR amyloidosis and assess their association with the cardiac amyloid burden as well as the association between CPET parameters and prognosis. Design, Setting and

Participants:

This single-center study evaluated patients diagnosed with ATTR amyloidosis from May 2019 to September 2022 who underwent CPET at the National Amyloidosis Centre. Of 1045 patients approached, 506 were included and completed the study. Patients were excluded if they had an absolute contraindication to CPET or declined participation. The mean (SD) follow-up period was 22.4 (11.6) months. Main Outcomes and

Measures:

Comparison of CPET parameters across disease phenotypes (ATTR with cardiomyopathy [ATTR-CM], polyneuropathy, or both [ATTR-mixed]), differences in CPET parameters based on degree of amyloid infiltration (as measured by cardiovascular magnetic resonance [CMR] with extracellular volume mapping), and association between CPET parameters and prognosis.

Results:

Among the 506 patients with ATTR amyloidosis included in this study, the mean (SD) age was 73.5 (10.2) years, and 457 participants (90.3%) were male. Impairment in functional capacity was highly prevalent. Functional impairment in ATTR-CM and ATTR-mixed phenotypes (peak mean [SD] oxygen consumption [VO2], 14.5 [4.3] mL/kg/min and 15.7 [6.2] mL/kg/min, respectively) was observed alongside impairment in the oxygen pulse, with ventilatory efficiency highest in ATTR-CM (mean [SD] ventilatory efficiency/volume of carbon dioxide expired slope, 38.1 [8.6]). Chronotropic incompetence and exercise oscillatory ventilation (EOV) were highly prevalent across all phenotypes, with both the prevalence and severity being higher than in heart failure from different etiologies. Worsening of amyloid burden on CMR was associated with decline in multiple CPET parameters, although chronotropic response and EOV remained abnormal irrespective of amyloid burden. On multivariable Cox regression analysis, peak VO2 and peak systolic blood pressure (SBP) were independently associated with prognosis (peak VO2 hazard ratio, 0.89 [95% CI, 0.81-0.99; P = .03]; peak SBP hazard ratio, 0.98 [95% CI, 0.97-0.99; P < .001]). Conclusions and Relevance In this study, ATTR amyloidosis was characterized by distinct patterns of functional impairment between all disease phenotypes. A high prevalence of chronotropic incompetence, EOV, and ventilatory inefficiency were characteristic of this population. CPET parameters were associated with amyloid burden by CMR and with peak VO2, and SBP, which have been shown to be independent predictors of mortality. These findings suggest that CPET may be useful in characterizing distinct patterns of functional impairment across the spectrum of amyloid infiltration and predicting outcomes, and potentially offers a more comprehensive method of evaluating functional capacity for future prospective studies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuropatias Amiloides Familiares / Insuficiência Cardíaca / Cardiomiopatias Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuropatias Amiloides Familiares / Insuficiência Cardíaca / Cardiomiopatias Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article